GlassScriptPhysician profile
Melissa Wells
NPI 1295346195
$1,900.48
in general payments reported to CMS, 2019-2025
13 companies · $395 in 2025
The $395 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $318 · 2023: $691 · 2024: $496 · 2025: $395.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,564 · Education: $18.55.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,564.22 |
| Education | $18.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $698.34 | 2022-2025 | Farxiga, Lokelma |
| Bayer Healthcare Pharmaceuticals INC. | $328.87 | 2022-2025 | |
| Opko Pharmaceuticals, LLC | $179.64 | 2022-2024 | Rayaldee |
| Travere Therapeutics, INC. | $162.86 | 2022-2025 | Filspari |
| Calliditas Therapeutics US INC. | $116.98 | 2024-2025 | Tarpeyo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $106.57 | 2025 | Jardiance |
| Daiichi Sankyo INC. | $82.87 | 2022 | |
| Horizon Therapeutics Plc | $66.36 | 2023 | Krystexxa |
| Kyowa Kirin, INC. | $55.84 | 2023 | Crysvita |
| Akebia Therapeutics INC | $40.68 | 2022-2023 | Auryxia |
| Otsuka America Pharmaceutical, INC. | $27.93 | 2025 | Jynarque |
| Vifor Pharma, INC. | $17.26 | 2022 | |
| Lilly USA, LLC | $16.28 | 2024 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Wells listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.